Tirzepatide Lyophilized Vials For Research Use GLP-1 GIP Dual Agonist

Tirzepatide vials is a prescription drug for injection, mainly used for weight management and blood sugar control in patients with type 2 diabetes. The product works by simulating two intestinal hormones, GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide), which can enhance insulin secretion, inhibit gastric emptying, and effectively control appetite, thereby helping patients lower blood sugar and lose weight. Tirzepatide adopts a once-weekly injection regimen, with a starting dose of usually 2.5 mg, which is gradually increased according to the patient's tolerance and efficacy, up to 15 mg.

Tirzepatide is a novel investigational peptide that functions as a dual agonist of the GIP (Glucose-dependent Insulinotropic Polypeptide) and GLP-1 (Glucagon-like Peptide-1) receptors. These two incretin hormones play critical roles in metabolic regulation, including glucose control, insulin secretion, and appetite suppression. By stimulating both receptors simultaneously, Tirzepatide has been shown in research to produce synergistic metabolic benefits that may surpass the effects of GLP-1 receptor agonists alone.

This dual-action mechanism helps to:

• Enhance insulin sensitivity and promote glucose-dependent insulin secretion.
• Suppress glucagon release after meals, improving postprandial glucose control.
• Slow gastric emptying, which helps regulate food intake and satiety.
• Reduce body weight by decreasing appetite and caloric intake.
• Improve overall metabolic function, particularly in models of Type 2 diabetes and obesity.